The global thyroid gland disorders treatment market was valued at USD 2.2 Bn in 2022 and is projected to reach USD 3.3 Bn by the end of 2031. The industry is anticipated to grow at a CAGR of 4.7% from 2023 to 2031, driven by the rising prevalence of thyroid disorders, increasing awareness regarding early diagnosis, and advancements in treatment therapies worldwide.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3113

Market Overview

Thyroid gland disorders majorly refer to medical conditions, such as hypothyroidism and hyperthyroidism, which may cause elevated or decreased levels of hormones that regulate the rate of metabolism in the body. Iodine deficiency is the most common cause of thyroid disorders. According to the National Center of Biotechnology Information, in August 2022, iodine was among the common nutrient deficiencies and is estimated to have adversely affected 35% to 45% of the global population in 2021.

According to a Statpearls article published in July 2022, a larger number of women aged 65 and above suffer from subclinical hyperthyroidism as compared to men; such that 0.4/1000 women and 0.1/1000 men are found battling hyperthyroidism after crossing the age of 65.

Analysts’ Viewpoint

Rise in demand for early detection of thyroid disorders is prompting several prominent players to develop innovative diagnostic tests. This, in turn, is projected to drive growth in the thyroid gland disorder treatment market over the next few years. The growing incidence of hypothyroidism and hyperthyroidism, and rising government initiatives to screen thyroid gland disorders, are fueling the global market demand.

Changing lifestyles, environmental influences, and enhanced diagnostic capabilities are boosting the growth of the thyroid gland disorders treatment industry. Additionally, the development of effective combination drug therapies with reduced side effects is anticipated to fuel the market for the treatment of thyroid dysfunction. Furthermore, evolving healthcare trends and advances in medical research are anticipated to offer lucrative business opportunities for drug manufacturers in the treatment of thyroid gland disorders over the next few years.

Analysis of Key Players

The competitive landscape is a blend of legacy pharmaceutical leaders and innovative biotech firms focusing on targeted oncology and biologics.

Leading companies operating in the thyroid gland disorders treatment market include:

• Merck KGaA
• Pfizer, Inc.
• Takeda Pharmaceutical Company Ltd.
• Allergan
• Sanofi S.A.
• AbbVie Inc.
• Lannett Company, Inc.
• Aspen
• Novartis AG
• Mylan N.V.

Strategic moves in 2026 focus on Early Screening Collaborations, with Merck KGaA and other leaders expanding diagnostic access in emerging markets to secure long-term patient pipelines.

Recent Developments (2025–2026)

• May 2026: Market reports indicate a surge in AI-driven ultrasound diagnostics, with new models achieving 97.8% accuracy in identifying malignant features in nodules.
• March 2026: Amgen strengthened its leadership in the Thyroid Eye Disease (TED) market, defending its biologics portfolio against emerging pipeline competitors.
• February 2026: Pharmaceutical focus shifted toward RET inhibitors for thyroid cancer, reflecting a broader pivot toward precision oncology.
• January 2026: Merck KGaA launched a global initiative to improve thyroid screening in underserved regions, particularly targeting asymptomatic hypothyroidism.
• Late 2025: Azurity Pharmaceuticals launched Adthyza, a new brand-name natural desiccated thyroid (NDT) drug, providing a rare new branded alternative for hormone replacement.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3113

Key Developments & Trends

• Precision Dosing: Growth in liquid and soft-gel formulations of Levothyroxine to improve absorption and dose precision.
• The Biologic Shift: Increasing use of monoclonal antibodies to treat the underlying autoimmune causes of thyroid-related complications.
• Digital Endocrine Health: Adoption of patient-facing apps to track symptoms and optimize thyroid medication timing.
• Point-of-Care Testing: Rising demand for rapid thyroid function tests (TSH/T4) that can be performed in primary care settings.
• Nuclear Medicine Advancements: Refined RAI protocols that minimize radiation exposure while maintaining high efficacy for hyperthyroidism.

Challenges

• The “Undiagnosed” Pool: Estimates suggest that up to 60% of people with thyroid disease are unaware of their condition, limiting immediate market capture.
• Generic Saturation: Massive competition from low-cost generics in the hypothyroidism space limits profit margins for branded manufacturers.
• Long-Term Monitoring Costs: While medications are affordable, the cumulative cost of lifetime blood tests and specialist visits remains a burden.
• Adherence Issues: Suboptimal patient compliance with daily thyroid medication leads to fluctuating hormone levels and poor outcomes.

Opportunities

• Targeted Oncology: High-value growth in therapies for Radioactive Iodine-Refractory thyroid cancers.
• Emerging Market Expansion: Massive untapped potential in Asia and Africa as middle-class populations seek endocrine screenings.
• Nutraceutical Synergy: Opportunities for companies to bundle thyroid treatments with specialized iodine or selenium supplements.
• Pediatric Care: Development of child-friendly, easy-to-administer formulations for congenital hypothyroidism.

Market Segmentation

➤ By Disorder Type

• Hypothyroidism (Market Leader ~65% share)
• Hyperthyroidism (Graves’ Disease)
• Thyroid Cancer (Fastest Growing in value)
• Thyroid Eye Disease (Niche/High-margin)

➤ By Drug Class

• Thyroid Hormones (Levothyroxine, Liothyronine – ~40.1% share)
• Antithyroid Agents (Thioamides like Methimazole)
• Biologics (For TED and Oncology)
• Radioactive Iodine

➤ By Route of Administration

• Oral (Dominant ~88.4% share)
• Parenteral (Injectable/IV for emergency care)

➤ By Distribution Channel

• Retail Pharmacies (Market Leader for chronic care)
• Hospital Pharmacies
• Online Pharmacies (Fastest growing CAGR)

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=3113&ltype=S

Conclusion

The thyroid gland disorders treatment market in 2026 is moving from hormone substitution to precision management. Through 2035, the market will be defined by AI-assisted diagnosis and targeted biologics. As the industry evolves beyond simple pills to integrated care models—combining genetic testing, smart imaging, and patient-specific dosing—the players that bridge the gap between diagnostic accuracy and therapeutic efficacy will lead the endocrine field.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com